Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560933 · ClinicalTrials.gov registry record
A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 186
- Enrollment target
NCT04560933: Completed study, sponsored by BioMarin Pharmaceutical.
NCT04560933 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 186 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04560933 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia A
Primary Outcome
To assess the Seroprevalence of antibodies to AAV vectors in patients with hemophilia A at Baseline
Interventions
- PROCEDURE Blood sample collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2020-08-25 |
| Est. Completion | 2023-10-20 |
What the finished NCT04560933 record still lists
NCT04560933 is an observational study that tracks outcomes without assigning an intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood sample collection is the first listed.
NCT04560933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04560933 about?
NCT04560933 is a clinical study titled "A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A". To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia A
What is the current status of trial NCT04560933?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2020-08-25. Estimated completion is 2023-10-20.
What interventions are being tested in trial NCT04560933?
The interventions under investigation include: Blood sample collection (PROCEDURE).
Who is sponsoring clinical trial NCT04560933?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI